Related Experiment Videos
Unanticipated plasma concentrations in two clozapine-treated patients.
C L Alfaro1, R K McClure, J E Vertrees
1National Institute of Mental Health, Bethesda, MD, USA. calfaro@nih.gov
The Annals of Pharmacotherapy
|September 28, 2001
Summary
Two patients with schizophrenia showed unexpectedly low clozapine plasma levels despite high-dose treatment. This highlights challenges in achieving therapeutic clozapine concentrations for some individuals.
Area of Science:
- Pharmacology
- Psychiatry
Background:
- Clozapine is an essential antipsychotic for treatment-resistant schizophrenia.
- Therapeutic drug monitoring is crucial for optimizing clozapine efficacy.
- Individual variability in clozapine metabolism can impact treatment outcomes.
Observation:
- Two medication-compliant patients with schizophrenia exhibited subtherapeutic clozapine plasma concentrations despite receiving high doses (800-900 mg/d).
- Dosage increases up to 1000 mg/d did not significantly raise clozapine levels in one patient.
- The ratio of clozapine plasma concentration to dose was lower than expected, suggesting altered pharmacokinetics.
Findings:
- Patients demonstrated significantly lower clozapine plasma concentrations than anticipated, even at maximum recommended doses.
- Achieving target therapeutic clozapine concentrations (e.g., >250 ng/mL) proved difficult.
- Potential reasons for low concentrations include increased cytochrome P450-mediated metabolism.
Implications:
- These cases underscore the need for careful monitoring and individualized dosing strategies for clozapine.
- Consideration of adjunctive therapies, such as clozapine metabolism inhibitors or other antipsychotics, may be necessary.
- Further research into the mechanisms of altered clozapine metabolism is warranted for optimizing treatment in non-responsive patients.